Full Press Release Details
Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results
New Jersey, August 27, 2020/ - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid
health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal
Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice. The test had two primary endpoints, safety
and immune response, both of which were met. The candidate was well tolerated and safe in mice that received the intramuscular
injection. A robust immune response was also observed.
study consisted of 50 mice, divided into 10 cohorts dosed with 5, 10 and 20 micrograms of the PRAK-03202 vaccine candidate. The
vaccine candidate was generally well tolerated and safe at all doses, with no adverse events reported. The vaccine candidate was
safe even at higher doses and generated a robust immune response against the three SARS-Cov2 antigens, S, E, and M. PRAK3202 elicited
neutralizing antibody titers levels in all the dose cohorts starting from 5 microgram to 20 microgram dose regimens. After three
doses in mice, all the groups' cohorts showed binding antibody levels similar to convalescent patients' levels.
Kundu, Co-Founder and Managing Director at Premas Biotech, commented: "We are happy to report that the vaccine candidate
study in mice has gone on well, and the results are positive and encouraging. We have engaged with the regulatory authorities
in India and are working towards the next steps under their guidance."
will seek to further characterize the immune response in the near term, while pursuing additional safety studies and later stage
animal testing with the goal of an investigational new drug (IND) submission to follow in the U.S. Premas continues to be engaged
formally with authorities and the Drug Controller in India. Both Akers and Premas are also communicating with regulators in the
Schreiber, Executive Chairman of Akers, stated, "We are very encouraged by the immune response and safety milestones met
in this study organized with our partner, Premas. We are currently moving towards enhanced dialogue with regulatory bodies in
both India and the United States and look forward to communicating updates with our investors in the near term."
Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic
& vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation.
Besides D-Crypt the difficult to express proteins expression platform, Premas' leading technologies include
Axtex-4D : an ex-vivo tissueoid generation platform and C-Qwence : a fully human naive
India based scFv antibody library. Further information is available on the Company's website: https://www.premasbiotech.com/
email: contact@premasbiotech.com
Akers Biosciences Inc.
Biosciences is pursuing rapid development and manufacturing of a COVID-19 vaccine candidate in collaboration with Premas Biotech
PVT Ltd.. In addition, the Company's board of directors continues to evaluate strategic alternatives for the company to
maximize shareholder value.
statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements
within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, statements of historical fact, and may be identified by words such as "anticipates,"
"assumes," "believes," "can," "could," "estimates," "expects,"
"forecasts," "guides," "intends," "is confident that", "may," "plans,"
"seeks," "projects," "targets," and "would," and their opposites and similar expressions
are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as
well as assumptions made by and information currently available to management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the company's
ability to achieve the expected benefits and costs of the transactions related to the acquisition of Cystron Biotech, LLC, including,
the timing of, and the company's ability to, obtain and maintain regulatory approvals for clinical trials of the company's
vaccine product candidate, the timing and results of the company's planned clinical trials for its vaccine product candidate,
the amount of funds the company requires for its vaccine product candidate, and the company's ability to maintain its license
with Premas Biotech PVT Ltd; challenges we may face in identifying, acquiring and operating new business opportunities; the outcome
of litigation or other proceedings to which the company is subject or which it may become subject to in the future; increased
levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the company
operates; the company's ability to retain and attract senior management and other key employees; the company's ability
to quickly and effectively respond to new technological developments; the company's ability to protect its trade secrets
or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing
on the company's proprietary rights; and the impact of the ongoing COVID-19 pandemic on the company's results of operations,
business plan and the global economy. A discussion of these and other factors, including risks and uncertainties with respect
to the company, is set forth in the company's filings with the SEC, including its annual report on Form 10-K filed with
the Securities and Exchange Commission, as may be supplemented or amended by the company's Quarterly Reports on Form 10-Q.
The company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
information on the company and its products can be found at www.akersbio.com.
Relations: Hayden IR
Mass, Managing Partner